αv integrin receptor antagonists

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S249000, C514S252020, C514S255050, C514S272000, C544S238000, C544S295000, C544S297000, C544S353000

Reexamination Certificate

active

07153862

ABSTRACT:
The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.

REFERENCES:
patent: 5652363 (1997-07-01), Khanna et al.
patent: 5872122 (1999-02-01), Bovy et al.
patent: 5952341 (1999-09-01), Duggan et al.
patent: 6048861 (2000-04-01), Askew et al.
patent: 6297249 (2001-10-01), Duggan et al.
patent: 2002/0086882 (2002-07-01), Konradi et al.
patent: WO 99/31061 (1999-06-01), None
patent: WO 00/72801 (2000-12-01), None

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

αv integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with αv integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and αv integrin receptor antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3669547

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.